Moleculin Biotech, a clinical stage pharmaceutical company, has reported encouraging data from a Phase 1 clinical trial of their drug, annamycin. The study revealed no evidence of cardiotoxicity in the subjects treated with the drug. As a result, Moleculin Biotech's shares soared by 17% to 72 cents. Despite experiencing a 33% decline in the stock value this year, this recent … [Read more...] about Moleculin Biotech Announces Positive Results From Phase 1 Clinical Trial of Annamycin
Footer
